Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3

Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission

Matthias Preusser on the phase 2 TUXEDO-3 trial

Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer

Abdalla Awidi on cancer control in the Middle East

ASCO 2025 Debrief

Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)

Richard Bryant on transperineal vs transrectal biopsy for prostate cancer

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

Ariana Znaor on cancer surveillance in the Eastern Mediterranean region

Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials

Yannick Romero on the changing landscape of national cancer control plans

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Emmy Boerrigter on dose selection of novel anticancer drugs